By Ronda Fears
Nashville, Aug. 12 - Alexion Pharmaceuticals Inc. priced a follow-on offering of 2.5 million shares at $26.75 each, discounted from Thursday's close of $27.32, for gross proceeds of $66.875 million.
Morgan Stanley & Co. was the bookrunner.
Cheshire, Conn.-based Alexion said proceeds would be used for general corporate purposes.
Earlier in the week, Alexion and partner Procter & Gamble said enrollment came in ahead of schedule in the pivotal phase III trial for pexelizumab, a drug being investigated for reducing mortality and heart attack following coronary artery bypass surgery.
| Issuer: | Alexion Pharmaceuticals Inc.
|
| Issue: | Follow-on stock offering
|
| Gross proceeds: | $66.875 million
|
| Shares: | 2.5 million shares
|
| Price: | $26.75 per share
|
| Bookrunner: | Morgan Stanley & Co.
|
| Pricing date: | Aug. 11
|
| Settlement date: | Aug. 17
|
| Ticker: | ALXN
|
| Stock price: | $27.32 at close Aug. 11
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
